Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

Por Wong, Kelly A., Worth, Angela, Martin, Ross, Svarovskaia, Evguenia, Brainard, Diana M., Lawitz, Eric, Miller, Michael D., Mo, Hongmei
Publicado em 2013

Peginesatide and Erythropoietin Stimulate Similar Erythropoietin Receptor-Mediated Signal Transduction and Gene Induction Events

Por Green, Jennifer M., Leu, Karen, Worth, Angela, Mortensen, Richard B., Martinez, David K., Schatz, Peter J., Wojchowski, Don M., Young, Peter R
Publicado em 2012

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

Por Bae, Andrew, Sun, Siu-Chi, Qi, Xiaoping, Chen, Xiaowu, Ku, Karin, Worth, Angela, Wong, Kelly A., Harris, Jeanette, Miller, Michael D., Mo, Hongmei
Publicado em 2010

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Por Lawitz, Eric J., Dvory-Sobol, Hadas, Doehle, Brian P., Worth, Angela S., McNally, John, Brainard, Diana M., Link, John O., Miller, Michael D., Mo, Hongmei
Publicado no Antimicrob Agents Chemother (2016)